MarketPeel
Insider Trading Intelligence
Pricing
…
RP

Raju Prasad

CRSP
CHIEF FINANCIAL OFFICER · CRISPR THERAPEUTICS AG · CIK 0001968317
FILING MIX · LIFETIME50%/50%
BUYS
23
SELLS
23
TOTAL VALUE
$8.52M
COMPANIES
1
ACTIVE SINCE
Mar 2023
HOLDINGS NOW
19,500
AVG SELL PX
$57.35
TRADE KIND
SHOWING 46 / 46
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
13 backtested trades · 8 horizons · 29 pending
Forward-return performance of every backtestable P/S trade by Raju Prasad, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d13+100.00%-5.18%-0.19%-4.99%-3.74%—
14d13+92.31%-9.81%-2.00%-7.81%-7.53%—
30d13+76.92%-5.90%-0.39%-5.51%-5.58%—
60d13+76.92%-5.83%+1.96%-8.81%-8.36%—
90d13+69.23%-7.35%+2.36%-9.71%-10.78%—
180d13(7 pending)+66.67%+2.87%+11.56%-8.70%-15.64%—
1y13(10 pending)+33.33%-4.37%+15.03%-19.40%-2.82%—
2y13(12 pending)+100.00%-33.63%+32.90%-66.52%-66.52%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
CRSP · 19,500 shares · as of May 29, 2026
025,00050,00075,000100,000202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 23 buys / 23 sellsCOVERAGE · 14 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
CRSP
CRISPR THERAPEUTICS AG
PURCHASEGRANT
Stock grant
19,500——19,500May 29, 2026Jun 2, 2026 ↗View →
CRSP
CRISPR THERAPEUTICS AG
SALE
Chief Financial Officer
3,708$46.78$173.5K15,565Mar 23, 2026Mar 24, 2026 ↗View →
CRSP
CRISPR THERAPEUTICS AG
PURCHASE
Chief Financial Officer
6,250——19,273Mar 20, 2026Mar 24, 2026 ↗View →
CRSP
CRISPR THERAPEUTICS AG
SALE
Chief Financial Officer
6,250——12,500Mar 20, 2026Mar 24, 2026 ↗View →
CRSP
CRISPR THERAPEUTICS AG
PURCHASEGRANT
Stock grant
27,500——27,500Mar 20, 2026Mar 24, 2026 ↗View →
CRSP
CRISPR THERAPEUTICS AG
PURCHASEGRANT
Stock grant
38,499——38,499Mar 20, 2026Mar 24, 2026 ↗View →
CRSP
CRISPR THERAPEUTICS AG
SALE
Chief Financial Officer
5,848$48.26$282.2K17,794Mar 16, 2026Mar 17, 2026 ↗View →
CRSP
CRISPR THERAPEUTICS AG
SALE
Chief Financial Officer
4,021$48.26$194.1K13,773Mar 16, 2026Mar 17, 2026 ↗View →
CRSP
CRISPR THERAPEUTICS AG
SALEGRANT
Gift
750——13,023Mar 16, 2026Mar 17, 2026 ↗View →
CRSP
CRISPR THERAPEUTICS AG
SALE
Chief Financial Officer
10,000——10,000Mar 14, 2026Mar 17, 2026 ↗View →
CRSP
CRISPR THERAPEUTICS AG
PURCHASE
Chief Financial Officer
10,000——16,767Mar 14, 2026Mar 17, 2026 ↗View →
CRSP
CRISPR THERAPEUTICS AG
PURCHASE
Chief Financial Officer
6,875——23,642Mar 14, 2026Mar 17, 2026 ↗View →
CRSP
CRISPR THERAPEUTICS AG
SALE
Chief Financial Officer
6,875——20,625Mar 14, 2026Mar 17, 2026 ↗View →
CRSP
CRISPR THERAPEUTICS AG
SALE10b5-1
10b5-1 plan
34,972$60.19$2.10M6,767Jan 22, 2026Jan 26, 2026 ↗View →
CRSP
CRISPR THERAPEUTICS AG
PURCHASE
Chief Financial Officer
34,972$45.15$1.58M41,739Jan 22, 2026Jan 26, 2026 ↗View →
CRSP
CRISPR THERAPEUTICS AG
SALE
Chief Financial Officer
34,972——41,667Jan 22, 2026Jan 26, 2026 ↗View →
CRSP
CRISPR THERAPEUTICS AG
PURCHASE
Chief Financial Officer
23,361$45.15$1.05M30,128Jan 6, 2026Jan 8, 2026 ↗View →
CRSP
CRISPR THERAPEUTICS AG
SALE10b5-1
10b5-1 plan
5,763$60.21$347.0K6,767Jan 6, 2026Jan 8, 2026 ↗View →
CRSP
CRISPR THERAPEUTICS AG
SALE10b5-1
10b5-1 plan
5,004$60.00$300.2K12,530Jan 6, 2026Jan 8, 2026 ↗View →
CRSP
CRISPR THERAPEUTICS AG
SALE
Chief Financial Officer
6,339——7,493Jan 6, 2026Jan 8, 2026 ↗View →
CRSP
CRISPR THERAPEUTICS AG
PURCHASE
Chief Financial Officer
6,339$44.31$280.9K36,467Jan 6, 2026Jan 8, 2026 ↗View →
CRSP
CRISPR THERAPEUTICS AG
SALE
Chief Financial Officer
23,361——76,639Jan 6, 2026Jan 8, 2026 ↗View →
CRSP
CRISPR THERAPEUTICS AG
SALE10b5-1
10b5-1 plan
18,933$60.18$1.14M17,534Jan 6, 2026Jan 8, 2026 ↗View →
CRSP
CRISPR THERAPEUTICS AG
SALE10b5-1
10b5-1 plan
5,472$56.33$308.3K7,767Dec 22, 2025Dec 23, 2025 ↗View →
CRSP
CRISPR THERAPEUTICS AG
SALE10b5-1
10b5-1 plan
1,000$56.89$56.9K6,767Dec 22, 2025Dec 23, 2025 ↗View →
CRSP
CRISPR THERAPEUTICS AG
SALE10b5-1
10b5-1 plan
3,528$55.10$194.4K13,239Dec 22, 2025Dec 23, 2025 ↗View →
CRSP
CRISPR THERAPEUTICS AG
PURCHASEGRANT
Stock grant
16,500——16,500Oct 3, 2025Oct 3, 2025 ↗View →
CRSP
CRISPR THERAPEUTICS AG
PURCHASEGRANT
Stock grant
20,000——20,000May 30, 2025Jun 3, 2025 ↗View →
CRSP
CRISPR THERAPEUTICS AG
SALE
Chief Financial Officer
2,197$41.23$90.6K16,767Mar 21, 2025Mar 24, 2025 ↗View →
CRSP
CRISPR THERAPEUTICS AG
SALE
Chief Financial Officer
6,250——18,750Mar 20, 2025Mar 24, 2025 ↗View →
CRSP
CRISPR THERAPEUTICS AG
PURCHASE
Chief Financial Officer
6,250——18,964Mar 20, 2025Mar 24, 2025 ↗View →
CRSP
CRISPR THERAPEUTICS AG
SALE
Chief Financial Officer
3,762$41.80$157.3K12,714Mar 17, 2025Mar 18, 2025 ↗View →
CRSP
CRISPR THERAPEUTICS AG
PURCHASEGRANT
Stock grant
36,666——36,666Mar 14, 2025Mar 18, 2025 ↗View →
CRSP
CRISPR THERAPEUTICS AG
PURCHASEGRANT
Stock grant
27,500——27,500Mar 14, 2025Mar 18, 2025 ↗View →
CRSP
CRISPR THERAPEUTICS AG
PURCHASE
Chief Financial Officer
10,000——16,476Mar 14, 2025Mar 18, 2025 ↗View →
CRSP
CRISPR THERAPEUTICS AG
SALE
Chief Financial Officer
10,000——20,000Mar 14, 2025Mar 18, 2025 ↗View →
CRSP
CRISPR THERAPEUTICS AG
PURCHASEGRANT
Stock grant
18,333——18,333Oct 16, 2024Oct 18, 2024 ↗View →
CRSP
CRISPR THERAPEUTICS AG
PURCHASEGRANT
Stock grant
15,000——15,000Oct 16, 2024Oct 18, 2024 ↗View →
CRSP
CRISPR THERAPEUTICS AG
PURCHASEGRANT
Stock grant
36,168——36,168Mar 20, 2024Mar 22, 2024 ↗View →
CRSP
CRISPR THERAPEUTICS AG
PURCHASEGRANT
Stock grant
25,000——25,000Mar 20, 2024Mar 22, 2024 ↗View →
CRSP
CRISPR THERAPEUTICS AG
SALE
Chief Financial Officer
3,524$72.69$256.2K6,476Mar 15, 2024Mar 18, 2024 ↗View →
CRSP
CRISPR THERAPEUTICS AG
SALE
Chief Financial Officer
10,000——30,000Mar 14, 2024Mar 18, 2024 ↗View →
CRSP
CRISPR THERAPEUTICS AG
PURCHASE
Chief Financial Officer
10,000——10,000Mar 14, 2024Mar 18, 2024 ↗View →
CRSP
CRISPR THERAPEUTICS AG
PURCHASEGRANT
Stock grant
13,832——13,832Oct 13, 2023Oct 17, 2023 ↗View →
CRSP
CRISPR THERAPEUTICS AG
PURCHASEGRANT
Stock grant
100,000——100,000Mar 14, 2023Mar 14, 2023 ↗View →
CRSP
CRISPR THERAPEUTICS AG
PURCHASEGRANT
Stock grant
40,000——40,000Mar 14, 2023Mar 14, 2023 ↗View →
Other insiders · CRSP
Loading peer insiders…
About this filer
CIK 0001968317
ROLE
Chief Financial Officer
PRIMARY
CRSP
COMPANIES
1
ACTIVE SINCE
Mar 2023
MARKETPEEL · /INSIDER/0001968317DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback